MyPatientPal: An App to Help Patients Manage Their Cancer Care
NCT03684005 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2021-03-02
Summary
MyPatientPal was developed in collaboration with both patient and oncologist stakeholders, is designed to facilitate such patient self-management through the daily reporting of side effects and medications.
Conditions
Interventions
- OTHER
-
MyPatientPal smartphone app
All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
Sponsors & Collaborators
-
Felicity Harper
lead OTHER
Principal Investigators
-
Felicity Harper, PhD · Associate Professor/PI
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-10-01
- Primary Completion
- 2019-10-08
- Completion
- 2019-10-11
Countries
- United States
Study Locations
More Related Trials
-
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
NCT03722680 ·Status: SUSPENDED ·Phase: PHASE2
-
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
NCT00078845 ·Status: COMPLETED ·Phase: PHASE2
-
Gemox as First and Second Line Therapy in Unknown Primary Cancer
NCT00353145 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation
NCT06199115 ·Status: RECRUITING ·Phase: NA
-
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
NCT04034355 ·Status: TERMINATED ·Phase: PHASE3
-
Long Term Effect of Oxaliplatin Treatment in Cancer Survivors
NCT02970526 ·Status: COMPLETED
-
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
NCT01262482 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
NCT00448552 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
NCT00483405 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
NCT00186277 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
NCT00743509 ·Status: COMPLETED ·Phase: PHASE2
-
CancerLife: Patient-Driven Solution in Cancer Care
NCT03371147 ·Status: COMPLETED ·Phase: NA
-
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
NCT00004173 ·Status: UNKNOWN ·Phase: PHASE1
-
Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003555 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
NCT00320515 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
NCT00744640 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
GPX-100 in Treating Patients With Solid Tumors
NCT00003403 ·Status: COMPLETED ·Phase: PHASE1
-
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line
NCT04764487 ·Status: UNKNOWN ·Phase: PHASE3
-
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
NCT00476086 ·Status: COMPLETED ·Phase: PHASE2
-
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
NCT07018622 ·Status: RECRUITING ·Phase: PHASE2
-
Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy
NCT03958747 ·Status: COMPLETED ·Phase: NA
-
Oxaliplatin in Treating Patients With Liver Cancer
NCT00052364 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
NCT00305188 ·Status: COMPLETED ·Phase: PHASE3
-
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
NCT00272051 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
NCT00831571 ·Status: COMPLETED